Jeffrey SH. Lin, James D. Johnson, Christoph H. Borchers, David F. Schaeffer, Janel L. Kopp
{"title":"Abstract A032: Interstitial insulin enrichment drives pancreatic cancer growth by enhancing cancer cell metabolic plasticity","authors":"Jeffrey SH. Lin, James D. Johnson, Christoph H. Borchers, David F. Schaeffer, Janel L. Kopp","doi":"10.1158/1538-7445.pancreatic25-a032","DOIUrl":null,"url":null,"abstract":"Metabolic diseases, such as type 2 diabetes, insulin resistance, and obesity, often coexist with pancreatic ductal adenocarcinoma (PDAC) and predict poor survival. Using a mouse model of diet-induced obesity, we showed that a high-fat diet (HFD) consumption that induces hyperinsulinemia, but not hyperglycemia, in mice accelerated the growth of xenografted patient-derived PDAC organoids (PDOs). Strikingly, even in the fasting state, insulin was highly enriched in the tumor interstitial fluid of pancreatic tumors under HFD. Modelling this elevated interstitial insulin concentration in vitro significantly increased PDO growth regardless of glucose levels. Mechanistically, chronic high-insulin exposure robustly enhances metabolic plasticity and nutrient utilization in PDOs by selectively upregulating distinct metabolic pathways in response to differences in extracellular glucose levels. Thus, the presence of robust insulin levels continuously supports tumor growth as glucose availability changes. Specifically, under low-glucose conditions, elevated insulin activates nutrient uptake machinery and amino acid metabolism, whereas it promotes aerobic glycolysis in high-glucose conditions. Pharmacological inhibition of these metabolic pathways attenuated insulin-mediated growth. Our study identifies insulin enrichment in the tumor-interstitial fluid as an important driver of metabolic adaptation in PDAC cells. Citation Format: Jeffrey SH. Lin, James D. Johnson, Christoph H. Borchers, David F. Schaeffer, Janel L. Kopp. Interstitial insulin enrichment drives pancreatic cancer growth by enhancing cancer cell metabolic plasticity [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research—Emerging Science Driving Transformative Solutions; Boston, MA; 2025 Sep 28-Oct 1; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2025;85(18_Suppl_3): nr A032.","PeriodicalId":9441,"journal":{"name":"Cancer research","volume":"97 1","pages":""},"PeriodicalIF":16.6000,"publicationDate":"2025-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1158/1538-7445.pancreatic25-a032","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Metabolic diseases, such as type 2 diabetes, insulin resistance, and obesity, often coexist with pancreatic ductal adenocarcinoma (PDAC) and predict poor survival. Using a mouse model of diet-induced obesity, we showed that a high-fat diet (HFD) consumption that induces hyperinsulinemia, but not hyperglycemia, in mice accelerated the growth of xenografted patient-derived PDAC organoids (PDOs). Strikingly, even in the fasting state, insulin was highly enriched in the tumor interstitial fluid of pancreatic tumors under HFD. Modelling this elevated interstitial insulin concentration in vitro significantly increased PDO growth regardless of glucose levels. Mechanistically, chronic high-insulin exposure robustly enhances metabolic plasticity and nutrient utilization in PDOs by selectively upregulating distinct metabolic pathways in response to differences in extracellular glucose levels. Thus, the presence of robust insulin levels continuously supports tumor growth as glucose availability changes. Specifically, under low-glucose conditions, elevated insulin activates nutrient uptake machinery and amino acid metabolism, whereas it promotes aerobic glycolysis in high-glucose conditions. Pharmacological inhibition of these metabolic pathways attenuated insulin-mediated growth. Our study identifies insulin enrichment in the tumor-interstitial fluid as an important driver of metabolic adaptation in PDAC cells. Citation Format: Jeffrey SH. Lin, James D. Johnson, Christoph H. Borchers, David F. Schaeffer, Janel L. Kopp. Interstitial insulin enrichment drives pancreatic cancer growth by enhancing cancer cell metabolic plasticity [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research—Emerging Science Driving Transformative Solutions; Boston, MA; 2025 Sep 28-Oct 1; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2025;85(18_Suppl_3): nr A032.
代谢性疾病,如2型糖尿病、胰岛素抵抗和肥胖,通常与胰腺导管腺癌(PDAC)共存,并预示着较差的生存率。使用饮食诱导的肥胖小鼠模型,我们发现高脂肪饮食(HFD)的消耗会导致小鼠高胰岛素血症,但不会导致高血糖,从而加速了异种移植患者来源的PDAC类器官(PDOs)的生长。引人注目的是,即使在空腹状态下,HFD下胰腺肿瘤的肿瘤间质液中胰岛素也高度富集。体外模拟这种升高的间质胰岛素浓度,无论葡萄糖水平如何,都显著增加了PDO的生长。从机制上讲,慢性高胰岛素暴露通过选择性上调不同的代谢途径来响应细胞外葡萄糖水平的差异,从而增强pdo的代谢可塑性和营养利用。因此,当葡萄糖可用性发生变化时,胰岛素水平的稳定持续支持肿瘤生长。具体来说,在低糖条件下,胰岛素升高激活营养摄取机制和氨基酸代谢,而在高糖条件下,胰岛素升高促进有氧糖酵解。这些代谢途径的药理抑制减弱了胰岛素介导的生长。我们的研究发现肿瘤间质液中的胰岛素富集是PDAC细胞代谢适应的重要驱动因素。引用格式:Jeffrey SH. Lin, James D. Johnson, Christoph H. Borchers, David F. Schaeffer, Janel L. Kopp。间质胰岛素富集通过增强癌细胞代谢可塑性驱动胰腺癌生长[摘要]。摘自:AACR癌症研究特别会议论文集:胰腺癌研究进展-新兴科学驱动变革解决方案;波士顿;2025年9月28日至10月1日;波士顿,MA。费城(PA): AACR;癌症研究2025;85(18_Suppl_3): nr A032。
期刊介绍:
Cancer Research, published by the American Association for Cancer Research (AACR), is a journal that focuses on impactful original studies, reviews, and opinion pieces relevant to the broad cancer research community. Manuscripts that present conceptual or technological advances leading to insights into cancer biology are particularly sought after. The journal also places emphasis on convergence science, which involves bridging multiple distinct areas of cancer research.
With primary subsections including Cancer Biology, Cancer Immunology, Cancer Metabolism and Molecular Mechanisms, Translational Cancer Biology, Cancer Landscapes, and Convergence Science, Cancer Research has a comprehensive scope. It is published twice a month and has one volume per year, with a print ISSN of 0008-5472 and an online ISSN of 1538-7445.
Cancer Research is abstracted and/or indexed in various databases and platforms, including BIOSIS Previews (R) Database, MEDLINE, Current Contents/Life Sciences, Current Contents/Clinical Medicine, Science Citation Index, Scopus, and Web of Science.